Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Remimazolam (Byfavo) is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. It has demonstrated a lower incidence of respiratory depression, hypoxemia, bradycardia, injection site pain, and dizziness compared to Propofol.
• The information was derived from seven studies on Remimazolam (Byfavo).
• In patients aged 60 years and older undergoing gastrointestinal endoscopic and colonoscopy procedures, Remimazolam showed a lower risk of bradycardia and hypoxemia than Propofol. However, Propofol had a shorter time to loss of consciousness.
• Compared with Midazolam during colonoscopy sedation, Remimazolam required fewer top-up doses, which reduced the need for rescue medication, indicating it as possibly a more effective safer profile drug.
• For clinical endoscopic procedure sedation when compared against Midazolam & placebo, Remimazolam displayed higher efficiency along with lesser incidences related to hypotension & hypoxemia, suggesting a better safety & effectiveness profile.
• Despite its low certainty according to GRADE assessment, evidence suggests that Remimazolam increases the success rate in procedural sedations, reduces the application requirement for rescue medications, while decreasing recovery time when compared against Midazolam.